Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data
Basel, Switzerland, 16 November 2020
Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza:
“We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment to controlling the COVID-19 pandemic.
“We are proud to support Moderna in the production of mRNA-1273. Our collaboration will allow for the manufacture of material equivalent to 400 million doses per year from Lonza’s facilities. Large-scale production began at our Portsmouth, US site at the end of September and we are on track to begin production at our Visp, Switzerland site before the end of the year.
“With positive interim results from both Moderna’s and Pfizer’s mRNA vaccine candidates, we are witnessing a major step forward in the evolution of vaccine technology, with the potential to change the way we manage infection and disease in the future.”